Drug news
IB 1001 (Inspiration Bio) filed at FDA for Haemophilia B
Inspiration Biopharmaceuticals has submitted a biologics license application (BLA) to the FDA for the approval of IB1001, an intravenous recombinant factor IX for the treatment and prevention of bleeding in Haemophilia B. Ipsen has European rights to the product.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.